Clinical trial · Observational
Molecular Analysis of Retinoblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retinoblastoma is a childhood tumor of the retina that affects approximately 1 in 18,000 children. Retinoblastoma is more prevalent in Central America, where most patients present with advanced intraocular and extraocular disease. Therefore, we have formed collaboration with Central American investigators to provide us with frozen retinoblastoma tumors from patients undergoing routine enucleation. The objective of this protocol is to begin to identify the mutations and gene expression changes that occur in retinoblastoma cells following RB1 gene inactivation in order to more effectively target chemotherapy for treating bilateral retinoblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Retinoblastoma | Retinoblastoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5 ml peripheral blood | Other | — | UNRESOLVED |
| Tissue samples taken from retinoblastoma | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Retinoblastoma
- interventionNames
- Other: Tissue samples taken from retinoblastoma
- Other: 5 ml peripheral blood
Primary outcomes (1)
- measure
- Identify genes exhibiting differential expression within intraocular disease tissue between patients having only intraocular involvement and those having extraocular involvement.
- timeFrame
- Indefinite
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Must have clinical diagnosis of retinoblastoma (to be confirmed histologically after enucleation) * Legal guardians must willing to sign an informed consent indicating that they are aware of this study and its possible benefits. Legal guardians will be given a copy of the consent form. * Patient is being seen at this AHOPCA institution: Exclusion Criteria: * Ophthalmologist or oncologist is concerned that sampling will interfere with staging. * Diagnosis other than retinoblastoma. * Affiliated hospital is unable to provide pathologic evidence of retinoblastoma.
References
Publications (0)
Data not yet available